Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients

Mortensen, J. H., van Haaften, W. T., Olesen, M. L., Karsdal, M., Olinga, P., Dijkstra, G. & Bay-Jensen, A. -C., 1-Feb-2017, In : Journal of Crohn's and Colitis. 11, p. S423-S424 2 p.

Research output: Contribution to journalMeeting AbstractAcademic

ID: 42705346